NuPathe, Inc. Message Board

HEADLINE: Deep Pockets Pfizer (PFE) Research And Development Stem Cell Unit In Cambridge United Kingdom To Begin Working With Bio-Matrix Scientific Group (BMSN)_Ventures Sierra World Equity Review.
Watch For Official Press Release Shortly, Remember When You Read It Sierra Told You First!

From the FDA sight
'Once the IND is submitted, the sponsor must wait 30 calendar days before initiating any clinical trials. During this time, FDA has an opportunity to review the IND for safety to assure that research subjects will not be subjected to unreasonable risk.'

BIOTECH NEWS STOCK REVIEW
2013 FDA Calender, Latest Clinical Trial Results And Biotech News Along With Biotech Stocks Forecast and Predictions
—FDA 2013 CALENDER AND CLINICAL TRIAL RESULTS—ALERT__BREAKING BIOTECH NEWS STOCK REVIEW BREAKS IT FIRST!_APPROVAL GRANTED_BIO-MATRIX SCIENTIFIC GROUP (BMSN) SAILS THROUGH FDA INVESTIGATIONAL NEW DRUG (IND) PROCESS, NEXT ORPHAN DRUG DESIGNATION PREDICTS BIOTECH NEWS STOCK REVIEW
Biotech News Stock Review Breaks It First!_Approval Granted_Bio-Matrix Scientific Group (BMSN) Sails Through FDA Investigational New Drug (IND) Process, Next Orphan Drug Designation Predicts Biotech News Stock Review.



Johnny is hearing from his very reliable sources that the FDA is shortly going to release the good news that BMSN shareholders have been waiting for, APPROVAL for HemaXellerate to move on and proceed with clinical trials. Wait for official word and then enjoy the ride shareholders of BMSN, check back for more updates!
Biotech Stock Share Price Rise Or Fall Projections For Week Of February 25th To March 1st 2013.

Utilizing a unique complex Japanese based technical indicator formula that has consistently yielded a 92% success accuracy rate here are Adam and Johnny’s forecasts for the coming week, before you freak out remember these stock calls are for the entire week. In other words a stock that is rated to go up will end up higher at the end of the week than it started and a stock rated lower will see it’s share price decline at week end from where it began! Caveat, these calls are based on current technical indicators, ANY POSITIVE NEWS is likely to override these forecasts!


Dynavax (DVAX) UP
Amarantus BioScience (AMBS) UP
Bio-Matrix Scientific Group (BMSN) DOWN
Arena Pharmaceuticals (ARNA) UP
Peregrine Pharmaceuticals (PPHM) UP
Every week we publish our highly accurate calls for about 20 biotech stocks. Our selections will almost always be higher or lower at the end of the week as we forecast, check back for our weekly picks.
FDA Approval Calender 2013

02/24/2013-Dynavax ”Heplisav”-Hepatitis B Vaccine-FDA Approval Decision
02/26/2013-Immunogen “Trastuzumab emtansine”-breast cancer-FDA Approval Decision
02/28/2013-Onyx Pharmaceuticals”Stivarga” -Gastrointestinal Stromal Tumors-FDA Approval Decision
03/01/2013-Zogenix ”Zohydro ER” -severe chronic pain-FDA Approval Decision
03/04/2013-DEPOMED ”Serada” - menopausal hot flashes-FDA Advisory Committee Meeting
03/07/2013-GlaxoSmithKline “BREO ELLIPTA” -chronic obstructive pulmonary disease-FDA Advisory Committee Meeting
03/27/2013-Ariad Pharmaceuticals “Ponatinib” -myeloid/lymphoblastic leukemia-FDA Approval Decision
03/27/2013-AP Pharma ”APF530″ -chemotherapy-induced nausea -FDA Approval Decision
03/31/2013-United Therapeutics “Oral Treprostinil” -pulmonary arterial hypertension-FDA Approval Decision
03/31/2013-Arena Pharmaceuticals “Belviq”-Obesity-EMA CHMP Panel Result
03/31/2013-Johnson & Johnson ”INVOKANA”-type 2 diabetes-FDA Approval Decision
04/15/2013-MAP PHARMACEUTICALS “LEVADEX” -migraine in adults-FDA Approval Decision


04/30/2013-Raptor Pharmaceuticals ”RP103″-nephropathic cystinosis-FDA Approval Decision
04/30/2013-Navidea Biopharmaceuticals “Lymphoseek”-lymphatic mapping procedures-FDA Approval Decision
05/12/2013-THERAVANCE ”Fluticasone furoate” -obstructive pulmonary disease-FDA Approval Decision
5/24/2013-Valeant Pharmaceuticals “Efinaconazole”-Toenail fungus infection-FDA Approval Decision
05/31/13-Affymax “Omontys”-Anemia in Kidney Dialysis Patients-EMA CHMP Panel Result
5/31/2013-Depomed “Serada”-menopausal hot flashes-FDA Approval Decision
05/31/13-Sanofi “Aubagio”-Multiple Sclerosis-EMA CHMP Panel Result
6/3/2013-GlaxoSmithKline “Dabrafenib”-Melanoma-FDA Approval Decision
6/3/2013-GlaxoSmithKline “Trametinib”-Melanoma-FDA Approval Decision
6/14/2013-Delcath Systems “ChemoSat”-Liver mets due to melanoma-FDA Approval Decision
06/30/2013-AVEO Pharmaceuticals “Tivopath”-Renal Cell Cancer-FDA Advisory Committee Meeting
06/30/2013-Biogen “BG-12″-Multiple Sclerosis-EMA CHMP Panel Result
07/01/2013-Merck “Suvorexant”-Insomnia-FDA Approval Decision
7/26/2013-AVEO Pharmaceuticals “Tivopath”-Renal Cell Cancer-FDA Approval Decision
7/26/2013-Forest Laboratories “evomilnacipran”-Depression-FDA Approval Decision
08/31/13-Ariad Pharmaceuticals “Iclusig”-Acute Lymphocytic Leukemia-EMA CHMP Panel Result
08/31/13-Celgene “Pomalyst”-Multiple Myeloma-EMA CHMP Panel Result
9/6/2013-Auxilium Pharmaceuticals “Xiaflex”-Peyronie’s Disease-FDA Approval Decision
12/17/2013-Antares Pharma “Otrexup”-Rheumatoid Arthritis-FDA Approval Decision
12/17/2013-GlaxoSmithKline “Dolutegravir”-HIV / AIDS-FDA Approval Decision

About Biotech News Stock Review
Adam and Johnny both love investing in biotech stocks, especially small companies that have promising drug pipelines.



Adam is an avid researcher and very meticulous in his stock selections, Adam previously worked for Sierra World Equity Review where he was instrumental in helping select numerous accurate FDA calls. Adam has a law degree from Yale and is also fluent in Mandarin which he studied at the University of Beijing.

Johnny is a executive for a large pharmaceutical company based in New Jersey, with years of experience in his position as Managing Director for mergers and acquisitions with with special focus on China, Johnny brings valuable insight and perspective to the blogs daily stock posts.

If you enjoy buying and selling stocks, occasionally trade stocks online and enjoy the thrill of seeing your stock breakout after positive FDA trial results, then perhaps you may enjoy our blog! To maintain impartiality we never hold positions in any of the stocks we blog about.



Biotech News Stock Review Blog
What Stock Adam And Johnny Are Long On But Do Not Blog About – Read the independent, DD it will blow you away-1000% Gains Likely This Year!
Disclaimer and Privacy Policy

Bio-Matrix' Regen BioPharma Executes LOI to Acquire Issued US Patent Covering Cancer Gene-Silencing Technology for Use in Treating Breast Cancer

Chinaman’s Chance_Not With Dynavax (DVAX)_FDA To Give Positive Approval For Heplisav_Share Price To Soar With Pfizer (PFE) Transaction Waiting In The Wings Predicts Sierra World Equity Review
Accurate Sierra Called It_CombiMatrix (CBMX) Surges 136%_ Acquisition Discussions With Life Technologies (LIFE) To Start Predicts Sierra World Equity Review
Taking The Blue Ribbon_Following Coming Acquisition #$%$ (MJNA) To Move To Nasdaq, Just You Wait And See Predicts Sierra World Equity Review
Sit Up And Take Notice_Parkervision (PRKR) Rises 73%_New News Next On Buyout As Qualcomm (QCOM) BOD Opts For Acquisition as Resolution Predicts Sierra World Equity Review
Cook Your Own Goose_Shorts To Be Spanked_Bio-Matrix Scientific Group (BMSN) To Release Official PR Within 14 Days Updating Discussions With Potential Buyout Suitors Predicts Sierra World Equity Review
February 21st 2013 Sierra’s latest forecasts and predictions
Lame Duck_Apple (APPL) Bows To VirnetX (VHC)_Legal Teams Poised To Unveil Settlement Offer Predicts Sierra World Equity Review

This is not only a new drug, but a new Paradigm.

About Bavituximab

Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that represents a new approach to treating cancer. Bavituximab is the lead drug candidate from the company's PS technology platform and is currently being tested in eight clinical trials, including three randomized Phase II trials in front-line and second-line non-small cell lung cancer and front-line pancreatic cancer, and five investigator-sponsored trials (ISTs) in additional oncology indications. PS is a highly immunosuppressive molecule usually located inside the membrane of healthy cells, but "flips" and becomes exposed on the outside of cells that line tumor blood vessels, creating a specific target for anti-cancer treatments. PS-targeting antibodies target and bind to PS and block this immunosuppressive signal, thereby enabling the immune system to recognize and fight the tumor.

Sentiment: Hold

Yes this is good news. However, the patients died. So
the news is emotionally tempered. The facts show that
this drug is having a significant impact on a cancer that
has baffled mankind. We are on the right
track here. The stocks brief sharp down turn is an emotional reaction.
Our first reaction is ..."What?? only a few more months of life.
Somhow think we are in the land of the living
going to the land of the dieing and when somone dies
there is somthing very wrong. But we are all dieing...
Hopfully going to the land of the living. This stock drop
has gotten me thinking. Me thinketh
I have too much stock on this side of eternity
and need to focus on the other side where the
lasting returns are assured. Eventually
we will all be 'longs' there.
Ok, that is my thought for the day.
I assume I will hear the wrath of my
younger reader but here it is.
I expect to see my 28,000 shares
to go back firmly in the green.
Until then I will try to not be emotionally
torn by this rip tide stock.

Sentiment: Hold

Type message

Sentiment: Hold

Type message

Sentiment: Strong Buy

I guess we will wake to the news on Monday. I am glad this is Super Bowl sunday. It will make the wait easier.

Sentiment: Hold

I will not mind if they go off at that level.

Sentiment: Strong Buy